Thrombocytopenia in high-risk patients with antiphospholipid syndrome

Journal of Thrombosis and Haemostasis

Volumn 16, Issue 3, 2018, Pages 529-532

  Pontara, E ^a   Banzato, A ^a   Bison, E ^a   Cattini, M G ^a   Baroni, G ^a   Denas, G ^a   Calligaro, A ^a   Marson, P ^a   Tison, T ^a   Ruffatti, A ^a   Pengo, V ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

catastrophic; phospholipid; platelets; syndrome; thrombocytopenia

Indexed keywords

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLATELET COUNT; PREVALENCE; PRIORITY JOURNAL; REMISSION; TERMINAL DISEASE; THROMBOCYTOPENIA; BLOOD; COMPLICATION; LEUKOPENIA; RISK; THROMBOCYTE; VERY ELDERLY; YOUNG ADULT;

IMMUNOGLOBULIN G; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BLOOD PLATELETS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; LEUKOPENIA; MALE; MIDDLE AGED; PLATELET COUNT; PREVALENCE; REMISSION INDUCTION; RISK; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 85042466839     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13947     Document Type: Article

References (24)

1. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell-Torres M, Hughes GR. The ‘primary’ antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68: 366–74.
2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.
3. Pengo V, Banzato A, Bison E, Denas G, Zoppellaro G, Bracco A, Padayattil Jose S, Hoxha A, Ruffatti A. Laboratory testing for antiphospholipid syndrome. Int J Lab Hematol 2016; 38(Suppl. 1): 27–3.
4. Cervera R. Antiphospholipid syndrome. Thromb Res 2017; 151(Suppl. 1): S43–7.
5. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19: 508–12.
6. Cervera R, Rodriguez-Pinto I, Colafrancesco S, Conti F, Valesini G, Rosario C, Agmon-Levin N, Shoenfeld Y, Ferrão C, Faria R, Vasconcelos C, Signorelli F, Espinosa G. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev 2014; 13: 699–707.
7. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, Khamashta MA, Shoenfeld Ye. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530–4.
8. Artim-Esen B, Diz-Küçükkaya R, I˙nanç M. The significance and management of thrombocytopenia in antiphospholipid syndrome. Curr Rheumatol Rep 2015; 17: 14.
9. Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician 2012; 85: 612–22.
10. Cuadrado MJ, Mujic F, Munoz E, Khamashta MA, Hughes GR. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 1997; 56: 194–6.
11. Uthman I, Godeau B, Taher A, Khamashta M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev 2008; 22: 187–94.
12. Veneri D, Franchini M, Randon F, Nichele I, Pizzolo G, Ambrosetti A. Thrombocytopenias: a clinical point of view. Blood Transfus 2009; 7: 75–85.
13. Cervera R, Tektonidou MG, Espinosa G, Cabral AR, Gonzalez EB, Erkan D, Vadya S, Adrogué HE, Solomon M, Zandman-Goddard G, Shoenfeld Y. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus 2011; 20: 174–81.
14. Krause I, Blank M, Fraser A, Lorber M, Stojanovich L, Rovensky J, Shoenfeld Y. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology 2005; 210: 749–54.
15. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–27.
16. Pengo V, Ruffatti A, Iliceto S. The diagnosis of the antiphospholipid syndrome. Pathophysiol Haemost Thromb 2006; 35: 175–80.
17. Bonnet S, Guedon A, Ribeil JA, Suarez F, Tamburini J, Gaujoux S. Indications and outcome of splenectomy in hematologic disease. J Visc Surg 2017; 154: 421–9.
18. Galli M, Finazzi G, Barbui T. Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment. Ann Med Interne (Paris) 1996; 147(Suppl. 1): 24–7.
19. Cervera R, Boffa MC, Khamashta MA, Hughes GR. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009; 18: 889–93.
20. Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, Tolosa C, Franz J, Selva A, Ingelmo M, Vilardell M. Hughes GRV Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 1994; 96: 3–9.
21. Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood 2014; 124: 611–22.
22. de Groot PG. Platelets as pivot in the antiphospholipid syndrome. Blood 2014; 124: 475–6.
23. Bontadi A, Ruffatti A, Falcinelli E, Giannini S, Marturano A, Tonello M, Hoxha A, Pengo V, Punzi L, Momi S, Gresele P. Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. Thromb Haemost 2013; 109: 901–8.
24. Baroni G, Banzato A, Bison E, Denas G, Zoppellaro G, Pengo V. The role of platelets in antiphospholipid syndrome. Platelets 2017; 7: 1–5.